Axovant Sciences Ltd (NASDAQ:AXON) traded down 6.3% on Monday . The company traded as low as $1.91 and last traded at $1.93. 888,305 shares were traded during trading, a decline of 70% from the average session volume of 2,965,120 shares. The stock had previously closed at $2.06.

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Axovant Sciences in a research report on Monday, August 13th. Oppenheimer reaffirmed a “hold” rating on shares of Axovant Sciences in a research report on Tuesday, June 12th. Zacks Investment Research downgraded shares of Axovant Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 15th. Jefferies Financial Group boosted their price objective on shares of Axovant Sciences from $3.00 to $5.00 and gave the company a “hold” rating in a research report on Monday, June 11th. Finally, BidaskClub downgraded shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 12th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $11.70.

The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 1.48. The stock has a market capitalization of $252.71 million, a P/E ratio of -0.98 and a beta of -0.01.

Axovant Sciences (NASDAQ:AXON) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.33). sell-side analysts forecast that Axovant Sciences Ltd will post -1.7 earnings per share for the current year.

In other news, Director George Bickerstaff bought 25,000 shares of the firm’s stock in a transaction on Thursday, August 9th. The stock was purchased at an average price of $2.07 per share, for a total transaction of $51,750.00. Following the transaction, the director now owns 50,000 shares in the company, valued at $103,500. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.00% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its position in Axovant Sciences by 2,519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 176,227 shares during the last quarter. BlackRock Inc. grew its position in Axovant Sciences by 3.4% in the 1st quarter. BlackRock Inc. now owns 3,012,515 shares of the biotechnology company’s stock worth $4,006,000 after purchasing an additional 100,296 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Axovant Sciences by 183.1% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 495,450 shares of the biotechnology company’s stock worth $1,120,000 after purchasing an additional 320,450 shares during the last quarter. A.R.T. Advisors LLC grew its position in Axovant Sciences by 148.9% in the 1st quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 249,074 shares during the last quarter. Finally, Millennium Management LLC grew its position in Axovant Sciences by 175.6% in the 1st quarter. Millennium Management LLC now owns 1,330,910 shares of the biotechnology company’s stock worth $1,770,000 after purchasing an additional 847,946 shares during the last quarter. Hedge funds and other institutional investors own 9.38% of the company’s stock.

About Axovant Sciences (NASDAQ:AXON)

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Featured Story: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.